{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:46:01Z","timestamp":1773661561628,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s10067-015-3079-7","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T02:38:00Z","timestamp":1443494280000},"page":"341-349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Persistent expression and function of P-glycoprotein on peripheral blood lymphocytes identifies corticosteroid resistance in patients with systemic lupus erythematosus"],"prefix":"10.1007","volume":"35","author":[{"given":"Amit","family":"Kansal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit K.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"key":"3079_CR1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1741-7015-8-77","volume":"29","author":"DJ Wallace","year":"2010","unstructured":"Wallace DJ (2010) Advances in drug therapy for systemic lupus erythematosus. BMC Med 29:77","journal-title":"BMC Med"},{"key":"3079_CR2","first-page":"349","volume-title":"The Hypothalamus\u2013Pituitary\u2013Adrenal Axis","author":"DP Franchimont","year":"2008","unstructured":"Franchimont DP, Chrousos GP (2008) Glucocorticoid Resistance in Inflammatory Diseases. In: Rey AD, Chrousos GP, Besedovsky HO (eds) The Hypothalamus\u2013Pituitary\u2013Adrenal Axis. Elsevier B.V, Amsterdam, Netherlands, pp 349\u2013358"},{"key":"3079_CR3","first-page":"3010","volume":"56","author":"WT Beck","year":"1996","unstructured":"Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF et al (1996) Methods to detect P-glycoprotein-associated multidrug resistance in patients\u2019 tumors: consensus recommendations. Cancer Res 56:3010\u20133020","journal-title":"Cancer Res"},{"key":"3079_CR4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-4615-4811-9_6","volume":"457","author":"R Advani","year":"1999","unstructured":"Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM et al (1999) Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol 457:47\u201356","journal-title":"Adv Exp Med Biol"},{"key":"3079_CR5","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V100.5.1910.h81702001910_1910_1912","volume":"100","author":"AF List","year":"2002","unstructured":"List AF, Kopecky KJ, Willman CL, Head DR, Slovak ML, Douer D et al (2002) Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 100:1910\u20131912","journal-title":"Blood"},{"key":"3079_CR6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/bjc.1996.316","volume":"74","author":"SC Linn","year":"1996","unstructured":"Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G (1996) p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 74:63\u201368","journal-title":"Br J Cancer"},{"key":"3079_CR7","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2003.08.002","volume":"3","author":"Y Richaud-Patin","year":"2004","unstructured":"Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L (2004) P-glycoprotein in autoimmune diseases. Autoimmun Rev 3:188\u2013192","journal-title":"Autoimmun Rev"},{"key":"3079_CR8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0091270007311568","volume":"48","author":"R Callaghan","year":"2008","unstructured":"Callaghan R, Crowley E, Potter S, Kerr ID (2008) P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 48:365\u2013378","journal-title":"J Clin Pharmacol"},{"key":"3079_CR9","first-page":"889","volume":"67","author":"T Tsuruo","year":"1983","unstructured":"Tsuruo T (1983) Reversal of acquired resistance to vinca alkaloids and anthracyclines antibiotics. Cancer Treat Rep 67:889\u2013894","journal-title":"Cancer Treat Rep"},{"key":"3079_CR10","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1073\/pnas.84.9.3004","volume":"84","author":"K Ueda","year":"1987","unstructured":"Ueda K, Cardaralli C, Gottesman MM, Pastan I (1987) Expression of a full-length cDNA for the human \u201cMDR-1\u201d gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A 84:3004\u20133008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3079_CR11","first-page":"840","volume":"7","author":"S Bourgeois","year":"1993","unstructured":"Bourgeois S, Gruol DJ, Newby BR, Rajah FM (1993) Expression of an MDR gene is associated with a new form of resistance to dexamethasone-induced apoptosis. Mol Endocrinol 7:840\u2013851","journal-title":"Mol Endocrinol"},{"key":"3079_CR12","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1210\/endo.139.4.5917","volume":"139","author":"OC Meijer","year":"1998","unstructured":"Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de Kloet ER (1998) Penetration of dexamethasone into brain corticosteroid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139:1789\u20131793","journal-title":"Endocrinology"},{"key":"3079_CR13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00431-006-0177-1","volume":"165","author":"AM Wasilewska","year":"2006","unstructured":"Wasilewska AM, Zoch-Zwierz WM, Pietruczuk M (2006) Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids. Eur J Pediatr 165:839\u2013844","journal-title":"Eur J Pediatr."},{"key":"3079_CR14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature09102","volume":"465","author":"C Guiducci","year":"2010","unstructured":"Guiducci C, Gong M, Xu Z, Gill M et al (2010) TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465:937\u2013941","journal-title":"Nature."},{"key":"3079_CR15","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","volume":"373","author":"PJ Barnes","year":"2009","unstructured":"Barnes PJ, Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. Lancet 373:1905\u20131917","journal-title":"Lancet."},{"key":"3079_CR16","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1677\/joe.0.1780339","volume":"178","author":"RJ Farrell","year":"2003","unstructured":"Farrell RJ, Kelleher D (2003) Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol 178:339\u2013346","journal-title":"J Endocrinol"},{"key":"3079_CR17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/s10165-009-0247-0","volume":"20","author":"S Tsujimura","year":"2010","unstructured":"Tsujimura S, Saito K, Nakayamada S, Tanaka Y (2010) Etanercept overcomes P-glycoprotein induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Mod Rheumatol 20:139\u2013146","journal-title":"Mod Rheumatol."},{"key":"3079_CR18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/rheumatology\/35.5.430","volume":"35","author":"JF Maillefert","year":"1996","unstructured":"Maillefert JF, Maynadie M, Tebib JG et al (1996) Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 35:430\u2013435","journal-title":"Br J Rheumatol"},{"key":"3079_CR19","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1200\/JCO.1998.16.11.3674","volume":"16","author":"DM Bradshaw","year":"1998","unstructured":"Bradshaw DM, Arceci RJ (1998) Clinical relevance of transmembrane drug efflux as mechanism of multidrug resistance. J Clin Oncol 16:3674\u20133690","journal-title":"J Clin Oncol"},{"key":"3079_CR20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/00001622-200009000-00011","volume":"12","author":"B Tan","year":"2000","unstructured":"Tan B, Piwnica-Worms D, Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450\u2013458","journal-title":"Curr Opin Oncol."},{"key":"3079_CR21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/0091270004264162","volume":"44","author":"T Hirano","year":"2004","unstructured":"Hirano T, Onda K, Toma T, Miyaoka M, Moriyasu F, Oka K (2004) MDR1 mRNA expressions in peripheral blood mononuclear cells of patients with ulcerative colitis in relation to glucocorticoid administration. J Clin Pharmacol 44:481\u2013486","journal-title":"J Clin Pharmacol."},{"key":"3079_CR22","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/art.21032","volume":"52","author":"S Tsujimura","year":"2005","unstructured":"Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y (2005) Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 52:1676\u20131683","journal-title":"Arthritis Rheum."},{"key":"3079_CR23","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 40:1725","journal-title":"Arthritis Rheum"},{"key":"3079_CR24","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1093\/ndt\/gfr150","volume":"26","author":"T Jafar","year":"2011","unstructured":"Jafar T, Prasad N, Agarwal V, Mahdi A, Gupta A, Sharma RK, Negi MP, Agrawal S (2011) MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 26:3968\u20133974","journal-title":"Nephrol Dial Transplant."},{"key":"3079_CR25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1590\/S0100-879X2008000900005","volume":"41","author":"TP Gonzalez","year":"2008","unstructured":"Gonzalez TP, Mucenic T, Brenol JC, Xavier RM, Schiengold M, Chies JA (2008) ABCB1 C1236T, G2677T\/A and C3435T polymorphisms in systemic lupus erythematosus patients. Braz J Med Biol Res 41:769\u2013772","journal-title":"Braz J Med Biol Res."},{"key":"3079_CR26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1067\/mcp.2001.117412","volume":"70","author":"RB Kim","year":"2001","unstructured":"Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189\u2013199","journal-title":"Clin Pharmacol Ther"},{"key":"3079_CR27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1067\/mcp.2002.127739","volume":"72","author":"W Siegmund","year":"2002","unstructured":"Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B et al (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572\u2013583","journal-title":"Clin Pharmacol Ther"},{"key":"3079_CR28","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1038\/sj.onc.1208955","volume":"24","author":"EK Baker","year":"2005","unstructured":"Baker EK, Johnstone RW, Zaleberg JR et al (2005) Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24:8061\u20138075","journal-title":"Oncogene"},{"key":"3079_CR29","first-page":"369","volume":"34","author":"C Huang","year":"2009","unstructured":"Huang C, Peiguo CAO, Zhaoxia XIE (2009) Relation of promoter methylation of mdr-1 gene and histone acetylation status with multidrug resistance in MCF-7\/Adr cells. J Cent South Univ (Med Sci) 34:369\u2013374","journal-title":"J Cent South Univ (Med Sci)"},{"key":"3079_CR30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI16153","volume":"111","author":"N Mishra","year":"2003","unstructured":"Mishra N, Reilly CM, Brown DR (2003) Phil Ruiz and Gary S Gilkeson. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr\/lpr mouse. J Clin Invest 111:539\u2013552","journal-title":"J Clin Invest"},{"key":"3079_CR31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4049\/jimmunol.168.2.597","volume":"168","author":"E Kelly","year":"2002","unstructured":"Kelly E, Won A, Refaeli Y, van Parijs L (2002) IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol 168:597\u2013603","journal-title":"J Immunol"},{"key":"3079_CR32","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4049\/jimmunol.153.2.604","volume":"153","author":"AT Luxembourg","year":"1994","unstructured":"Luxembourg AT, Cooper NR (1994) T cell-dependent, B cell-activating properties of antibody-coated small latex beads: a new model for B cell activation. J Immunol 153:604\u2013614","journal-title":"J Immunol"},{"key":"3079_CR33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/j.1365-2443.2004.00803.x","volume":"9","author":"S Tsujimura","year":"2004","unstructured":"Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K et al (2004) Transcriptional regulation of multidrug resis-tance-1 gene by interleukin-2 in lymphocytes. Genes Cells 9:1265\u20131273","journal-title":"Genes Cells"},{"key":"3079_CR34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3892\/etm.2012.667","volume":"4","author":"B Zhang","year":"2012","unstructured":"Zhang B, Shi Y, Lei TC (2012) Detection of active P-glycoprotein in systemic lupus erythematosus patients with poor disease control. Exp Ther Med 4:705\u2013710","journal-title":"Exp Ther Med."},{"key":"3079_CR35","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","volume":"19","author":"N Miyasaka","year":"2009","unstructured":"Miyasaka N, Kawai S, Hashimoto H (2009) Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. Mod Rheumatol 19:606\u2013615","journal-title":"Mod Rheumatol."},{"key":"3079_CR36","first-page":"6","volume":"28","author":"A Uchino","year":"2010","unstructured":"Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furugo I et al (2010) Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol 28:6\u201312","journal-title":"Clin Exp Rheumatol."},{"key":"3079_CR37","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1177\/0961203312448105","volume":"21","author":"S Wang","year":"2012","unstructured":"Wang S, Li X, Qu L, Wang R, Chen Y, Li Q, He X, Zhang X, Wang H, Wu J, Xu Y, Chen J (2012) Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus 21:1025\u20131035","journal-title":"Lupus."},{"key":"3079_CR38","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/0961203312442259","volume":"21","author":"W Chen","year":"2012","unstructured":"Chen W, Liu Q, Chen W, Tang X, Fu P et al (2012) Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 21:944\u2013952","journal-title":"Lupus."},{"key":"3079_CR39","doi-asserted-by":"crossref","first-page":"c165","DOI":"10.1159\/000346149","volume":"121","author":"H Tanaka","year":"2013","unstructured":"Tanaka H, Watanabe S, Aizawa-Yashiro T, Oki E, Kumagai N, Tsuruga K, Ito E (2013) Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract 121:c165\u2013c173","journal-title":"Nephron Clin Pract."},{"key":"3079_CR40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1620\/tjem.227.281","volume":"227","author":"J Deng","year":"2012","unstructured":"Deng J, Huo D, Wu Q, Yang Z, Liao Y (2012) A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med 227:281\u2013288","journal-title":"Tohoku J Exp Med."},{"key":"3079_CR41","first-page":"62","volume":"31","author":"Y Fei","year":"2013","unstructured":"Fei Y, Wu Q, Zhang W, Chen H, Hou Y et al (2013) Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol 31:62\u201368","journal-title":"Clin Exp Rheumatol"},{"key":"3079_CR42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20130301","volume":"211","author":"R Radha","year":"2014","unstructured":"Radha R, Lina K, Kelly MK, Djuretic IM, Carlson TJ, Quintero MA, McCauley JL, Abreu MT, Derya U, Sundrud MS (2014) Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med 211:89\u2013104","journal-title":"J Exp Med"},{"key":"3079_CR43","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1186\/ar2964","volume":"12","author":"K Shah","year":"2010","unstructured":"Shah K, Lee W-W, Lee S-H, Kim SH, Kang SW, Craft J, Kang I (2010) Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 12:R53","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-3079-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-015-3079-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-015-3079-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T17:57:30Z","timestamp":1692035850000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-015-3079-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["3079"],"URL":"https:\/\/doi.org\/10.1007\/s10067-015-3079-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]}}}